Atrium Therapeutics, Inc. (RNA) News
Follow Atrium Therapeutics, Inc. (RNA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Atrium Therapeutics Q3 2026 Net Loss Widens to $4.27 Million
EQUITY | Nov 12, 2026, 09:27 PM UTC
M
Atrium Therapeutics Q3 Collaboration Revenue Rises on BMS Milestone
EQUITY | Nov 12, 2026, 09:18 PM UTC
M
Atrium Therapeutics shares rise on $50M private placement
Atrium Therapeutics entered a securities-purchase agreement for a private placement, with shares up 12% to $8.90 in premarket trading.
EQUITY | Oct 08, 2026, 11:45 AM UTC
L
Pharma sector doubles down on AI to slash costs, timelines
Pharmaceutical companies are increasingly turning to artificial intelligence to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency across their pipelines.Industry
NEWS | Sep 29, 2026, 01:35 PM UTC
L
RNA - Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
RNA - Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
NEWS | Sep 21, 2026, 08:30 PM UTC
L
New biotech advances RNA therapeutics for rare cardiomyopathies
New biotech advancing RNA therapeutics for rare genetic cardiomyopathies. Lead PRKAG2 program is in phase I/II, with proof-of-concept data expected next year, alongside strategic collaborations and a broader pipeline.
EQUITY | Sep 08, 2026, 01:39 PM UTC
L
New biotech advances RNA therapies for rare genetic cardiomyopathies
Unresolved biotech is advancing RNA therapeutics for rare genetic cardiomyopathies, focusing on PRKAG2 and PLN syndromes. Lead program is in Phase I/II, with proof-of-concept data expected next year and strategic partner
EQUITY | Sep 08, 2026, 01:04 PM UTC
L
RNA - Atrium Therapeutics to Participate in Upcoming Investor Conferences
RNA - Atrium Therapeutics to Participate in Upcoming Investor Conferences
EQUITY | Sep 02, 2026, 12:01 PM UTC
L
Atrium Therapeutics announces inducement grants under Nasdaq Rule 5635(c)(4)
Atrium Therapeutics (RNA) announces inducement grants under Nasdaq Listing Rule 5635(c)(4), per the company’s release.
REGULATION | Aug 20, 2026, 10:25 PM UTC
L
Atrium Therapeutics reports Second Quarter 2026 financial results
Atrium Therapeutics (RNA) reports its Second Quarter 2026 financial results, per TradeXchange Newsdesk, with no figures or additional detail included in the feed.
EARNINGS | Aug 13, 2026, 08:45 PM UTC
L
MRVI Maravai unit TriLink wins China patent for CleanCap mRNA capping technology Maravai LifeSciences’ TriLink unit secured a newly issued C
MRVI Maravai unit TriLink wins China patent for CleanCap mRNA capping technology Maravai LifeSciences’ TriLink unit secured a newly issued China patent for CleanCap mRNA capping technology, strengthening IP Protection in
GEOPOLITICS | Jul 20, 2026, 08:06 PM UTC
L
Atrium Therapeutics Says FDA Clears Phase 1/2 Trial of ATR 1072 in PRKAG2 Syndrome
() -- Atrium Therapeutics (RNA) said Tuesday the US Food and Drug Administration cleared its investigational new drug application for its lead product candidate ATR 1072, allowing the company to advance a phase 1/2 clini
REGULATION | Jul 14, 2026, 11:18 AM UTC
L
Atrium Therapeutics announces FDA clearance of ATR 1072 IND application
Atrium Therapeutics...
REGULATION | Jul 14, 2026, 10:36 AM UTC